Are there different strategies you would utilize to monitor and manage potential resistance in patients with CML receiving asciminib?
Does asciminib result in harder to treat mutations if they develop?
Community PollStarted
Does the potential / pending resistance mutation profile of asciminib influence your decision to use it?
44 physicians have voted
Join Mednetto vote and see how they answered.
2 Answers
Mednet Member
Hematology · University of Washington School of Medicine
Answered on
Overall, I use similar monitoring strategies for all CML therapies, including what responses or loss of response prompt me to consider assessment for mutations that confer therapy resistance. Sometimes it is difficult to differentiate non-adherence vs emerging resistance, and thus it is important to...
Join for free or sign in to see the full answer
Mednet MemberInvited Expert
Medical Oncology · Georgia Cancer Center at Augusta University
Answered on
The monitoring is the same as we do for patients on any TKI. The unique aspect regarding mutations is that we mostly see mutations in the myristoyl pocket among patients with resistance to asciminib. I do not consider these harder to treat, as they would be sensitive in principle to conventional TKI...
Join for free or sign in to see the full answer